https://lnkd.in/enpEpNq9 registrations open! reserve your seat soon.. BRITISH DERMATOLOGICAL NURSING GROUP Dermatology Times European Academy of Dermatology and Venereology dermatologists Big Country Dermatology Pharmacy Rheumatology News Bench to Bedside Rheumatology American College of Rheumatology RheumNow Rheumatology News Lupus Consulting Lupus Foundation of America, Inc.
King's Centre for Nephrology, Urology and Transplantation’s Post
More Relevant Posts
-
Could patients with atopic dermatitis reduce dupilumab dosing frequency and still maintain disease control? Read about this, and more of the latest dermatology research, in our research briefing https://buff.ly/3F2Y0kn.
To view or add a comment, sign in
-
Botulinum toxin type A can worsen symptoms of myasthenia gravis (MG) or unmask latent disease, according to a study published in the Journal of the European Academy of Dermatology and Venereology. This is because both botulinum toxin type A and MG target the same neuromuscular structures. Botulinum toxin type A should, therefore, be avoided in patients with known MG. An accurate medical history should be obtained, and a physical examination should be performed to identify any possible sign of the disease in all people undergoing the injection, the study authors noted. Read more here: https://lnkd.in/enBmjDcB #MyastheniaGravis #ManagingMG #AutoimmuneDisease #NeuromuscularDisease #RareDisease
To view or add a comment, sign in
-
Thinking about switching to a biosimilar treatment for your psoriasis? Here's the lowdown! 👇 A new study at the American Academy of Dermatology examined the effects of switching from brand name medications to biosimilars in patients with psoriasis. Click the link to learn more about these promising findings and what they could mean for you! https://lnkd.in/eb7eM9ZF
AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars
centerforbiosimilars.com
To view or add a comment, sign in
-
dupilumab and tralukinomab, here we go))).
NEW: The American Academy of Dermatology has published new guidelines for the treatment of adults with #AtopicDermatitis using phototherapy and systemic therapies. The guideline authors strongly recommend dupilumab, tralokinumab, baricitinib, abrocitinib, and upadacitinib; conditionally recommend phototherapy, cyclosporine, methotrexate, azathioprine, and mycophenolate, and do not recommend systemic corticosteroids. https://lnkd.in/gQNX9_gX
Updated AAD Guidelines for the Management of AD with Phototherapy and Systemic Therapies
dermatologytimes.com
To view or add a comment, sign in
-
🔬 Unveiling Dermatology & Immunology Insights! 🌟 CTM's Best Group of the Month for September, led by András Bánvölgyi, explores melanoma, lupus, and hidradenitis suppurativa. 📊💪 💡 Targeting early diagnosis and effective treatments, they aim to reduce the 8-year diagnostic delay for hidradenitis suppurativa. Led by Bernadett Hidvégi, they explore lupus, modern imaging, and teledermatology's potential in future healthcare. 🩹📅 Discover more about their groundbreaking work: https://lnkd.in/dHBeQh4h 🌐👩🔬 #DermatologyResearch #ImmunologyInsights #CTMInnovation
„It is important to find the most effective treatments”
tm-centre.org
To view or add a comment, sign in
-
Yesterday, Dr. Patrick Shannon had the chance to sit down with David Sess of WKBN to share more information on Optima Research and clinical trials, located in Boardman, OH. In partnership with Advanced Dermatology & Skin Cancer Center, Optima Research gives patients the opportunity to participate in cutting edge research that can help them overcome and improve difficult and complex skin conditions. Check out this story to learn more! ➡️ https://lnkd.in/eFJkzK2e
Local clinical trials target skin disorders
https://www.wkbn.com
To view or add a comment, sign in
-
MD, PhD. Dermatologist - Centro Hospitalar Universitário do Porto | Professor of Dermatology - University of Porto | Head of Clinical Trials Department CAC-ICBAS/CHUdSA | Instituto Médico de Estudos Imunológicos
Just published on American Journal of Clinical Dermatology! This study analysed the largest cohort of psoriasis patients with untreated/incompletely treated latent tuberculosis who received IL-17 or IL-23 inhibitors. Over 400 psoriasis patients from 5 different countries (Brazil, Greece, Italy, Portugal and Spain) with newly diagnosed LTBI were included, of which 37.8% received incomplete or no chemoprophylaxis. Chemoprophylaxis may be waived if IL-17 inhibitors and IL-23 inhibitors are used, specially if the risk for developing complications related to chemoprophylaxis exists. “Treatment of Psoriasis Patients with Latent Tuberculosis Using IL‑17 and IL‑23 Inhibitors: A Retrospective, Multinational, Multicentre Study”
To view or add a comment, sign in